Evidence map›Paper›PMID 34556099›Full record

ArticleBMC medical ethics2021

Ethical considerations for involving adolescents in biomedical HIV prevention research.

Rita Nakalega, Carolyne Akello, Brenda Gati, Clemensia Nakabiito, Monica Nolan, Betty Kamira, Juliane Etima, Teopista Nakyanzi, Doreen Kemigisha, Sophie C Nanziri and 11 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in BMC medical ethics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03593655 (A Phase 2a Crossover Trial Evaluating the Safety of and Adherence to a Vaginal Matrix Ring Containing Dapivirine and Oral Emtricitabine/Tenofovir Disoproxil Fumarate in an Adolescent and Young Adult Female Population), which is not on this map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03593655 phase2completednot on this map

A Phase 2a Crossover Trial Evaluating the Safety of and Adherence to a Vaginal Matrix Ring Containing Dapivirine and Oral Emtricitabine/Tenofovir Disoproxil Fumarate in an Adolescent and Young Adult Female Population

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2019 to 2021Enrolled247ConditionsHIV InfectionsArmsDapivirine vaginal ring, FTC/TDF
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 3 institutions in 3 countries.

Rita NakalegaMakerere University-Johns Hopkins University (MU-JHU) Research Collaboration, Kampala, Uganda. rnakalega@mujhu.org.
Carolyne AkelloMakerere University-Johns Hopkins University (MU-JHU) Research Collaboration, Kampala, Uganda.
Brenda GatiMakerere University-Johns Hopkins University (MU-JHU) Research Collaboration, Kampala, Uganda.
Clemensia NakabiitoMakerere University-Johns Hopkins University (MU-JHU) Research Collaboration, Kampala, Uganda.
Monica NolanMakerere University-Johns Hopkins University (MU-JHU) Research Collaboration, Kampala, Uganda.
Betty KamiraMakerere University-Johns Hopkins University (MU-JHU) Research Collaboration, Kampala, Uganda.
Juliane EtimaMakerere University-Johns Hopkins University (MU-JHU) Research Collaboration, Kampala, Uganda.
Teopista NakyanziMakerere University-Johns Hopkins University (MU-JHU) Research Collaboration, Kampala, Uganda.
Doreen KemigishaMakerere University-Johns Hopkins University (MU-JHU) Research Collaboration, Kampala, Uganda.
Sophie C NanziriMakerere University-Johns Hopkins University (MU-JHU) Research Collaboration, Kampala, Uganda.
Stella NanyongaMakerere University-Johns Hopkins University (MU-JHU) Research Collaboration, Kampala, Uganda.
Maria Janine NambusiMakerere University-Johns Hopkins University (MU-JHU) Research Collaboration, Kampala, Uganda.
Emmie MulumbaMakerere University-Johns Hopkins University (MU-JHU) Research Collaboration, Kampala, Uganda.
Florence BiiraMakerere University-Johns Hopkins University (MU-JHU) Research Collaboration, Kampala, Uganda.
Hadijah Kalule NabunyaMakerere University-Johns Hopkins University (MU-JHU) Research Collaboration, Kampala, Uganda.
Simon Afrika AkasiimaMakerere University-Johns Hopkins University (MU-JHU) Research Collaboration, Kampala, Uganda.
Joselyne NansimbeMakerere University-Johns Hopkins University (MU-JHU) Research Collaboration, Kampala, Uganda.
Joel MaenaMakerere University-Johns Hopkins University (MU-JHU) Research Collaboration, Kampala, Uganda.
Juliet Allen BabiryeMakerere University-Johns Hopkins University (MU-JHU) Research Collaboration, Kampala, Uganda.
Kenneth NgureDepartment of Global Health, University of Washington, Seattle, USA.
Andrew MujugiraDepartment of Global Health, University of Washington, Seattle, USA.
MUJHU Research Collaboration · UGMakerere University · UGSeattle University · US

Funding

Microbicide Trials NetworkUM1AI068633 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI HILLIER, SHARON L. · 2011 to 2021
$175.0M
Statistical and Data Management Center (SDMC): Microbicide Trials NetworkUM1AI068615 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BROWN, ELIZABETH RENATA · 2011 to 2021
$66.5M
WG3: HIV, Co-infections and Co-morbiditiesP30AI036219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI Alan David Levine · 1994 to 2026
$50.0M
The Johns Hopkins University - Uganda Clinical Trials UnitUM1AI069530 · NIAID · JOHNS HOPKINS UNIVERSITY · PI MARY Glenn Fowler, Philippa Musoke · 2012 to 2026
$34.8M
Laboratory Center (LC): Microbicide Trials NetworkUM1AI106707 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI MELLORS, JOHN W, ROHAN, LISA CENCIA · 2014 to 2021
$27.1M
HIV Self Testing to Empower Prevention Choices in Sex WorkersK43TW010695 · FIC · INFECTIOUS DISEASES INSTITUTE · PI MUJUGIRA, ANDREW · 2017 to 2021
$530k
FIC NIH HHS K43 TW010695NIAID NIH HHS P30 AI036219NIAID NIH HHS UM1 AI068615NIAID NIH HHS UM1 AI068633NIAID NIH HHS UM1 AI069530NIAID NIH HHS UM1 AI106707
6 · The paper itself

Abstract

backgroundInvolvement of adolescent girls in biomedical HIV research is essential to better understand efficacy and safety of new prevention interventions in this key population at high risk of HIV infection. However, there are many ethical issues to consider prior to engaging them in pivotal biomedical research. In Uganda, 16-17-year-old adolescents can access sexual and reproductive health services including for HIV or other sexually transmitted infections, contraception, and antenatal care without parental consent. In contrast, participation in HIV prevention research involving investigational new drugs requires adolescents to have parental or guardian consent. Thus, privacy and confidentiality concerns may deter adolescent participation. We describe community perspectives on ethical considerations for involving adolescent girls in the MTN 034 study in Uganda.

methodsFrom August 2017 to March 2018, we held five stakeholder engagement meetings in preparation for the MTN 034 study in Kampala, Uganda (NCT03593655): two with 140 community representatives, two with 125 adolescents, and one with 50 adolescents and parents. Discussions were moderated by the study team. Proceedings were documented by notetakers. Summary notes described community perspectives of adolescent participation in HIV research including convergent, divergent or minority views, challenges, and proposed solutions.

resultsMost community members perceived parental or guardian consent as a principal barrier to study participation due to concerns about adolescent disclosure of pre-marital sex, which is a cultural taboo. Of 125 adolescent participants, 119 (95%) feared inadvertent disclosure of sexual activity to their parents. Community stakeholders identified the following critical considerations for ethical involvement of adolescents in HIV biomedical research: (1) involving key stakeholders in recruitment, (2) ensuring confidentiality of sensitive information about adolescent sexual activity, (3) informing adolescents about information to be disclosed to parents or guardians, (4) offering youth friendly services by appropriately trained staff, and (5) partnering with community youth organizations to maximize recruitment and retention.

conclusionsStakeholder engagement with diverse community representatives prior to conducting adolescent HIV prevention research is critical to collectively shaping the research agenda, successfully recruiting and retaining adolescents in HIV clinical trials and identifying practical strategies to ensure high ethical standards during trial implementation.

Indexed as

Acquired Immunodeficiency SyndromeBiomedical ResearchHIV InfectionsAdolescentConfidentialityFemaleHumansPregnancyUgandaAdolescent girlsBiomedical HIV prevention researchEthicsStakeholder engagementUganda

Identifiers

PMID34556099
PMCPMC8461968
OpenAlexW3201469545

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.